DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

NCT03599518 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

20

Enrollment

INDUSTRY

Sponsor class

Stopped This study was terminated based on a business decision by the Sponsor.

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: DS-1205c
DRUG: Gefitinib

Sponsor

Daiichi Sankyo Co., Ltd.